The Ellipse and Assura portfolio of implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds) received CE mark in Europe, St. Jude Medical announced.
The devices include an algorithm that adjusts shocking configurations within the device to ensure the delivery of high-voltage therapy in the event of an electrical short in one portion of the system. Another algorithm is designed to reduce the risk of inappropriate shocks by differentiating lead noise (over-sensing of electrical signals) from true ventricular tachycardia or ventricular fibrillation episodes requiring therapy.
In addition, the defibrillators feature coating on the device can that has been shown to significantly reduce friction between the device and leads that potentially can cause lead-to-can abrasion.
St. Jude Medical is based in St. Paul, Minn.